Assessing the validity and reliability and establishing norm values for a selective attention test in a Turkish sample of 6-14-year-old participants.

Selective attention is a cognitive skill that allows an individual to focus on a particular input for further processing while simultaneously suppressing irrelevant or distracting information. In this study, we have developed a new test to assess selective attention-the Cognitive Skills Assessment of Minerva (CSM) Selective Attention Test-and have established selective attention norm values for Turkish individuals aged 6-14 years. This new online selective attention assessment test includes the flanker task. We employed split-half reliability to prove the reliability of the test. Based on the analysis, there was no significant difference between the groups, indicating that the test is reliable. We used criterion-related validity (congruent validity) analysis to evaluate the CSM Selective Attention Test. The correlation between the results of the new test and the Eriksen Flanker Test showed that the new test is valid. Finally, we conducted a comprehensive norm study with 2,297 participants aged 6-14 years from 12 different regions and schools in Turkey. According to the analysis of variance, age but not gender is a distinguishing factor for selective attention. We subsequently established norm values for each age group. The findings also show that the CSM Selective Attention Test provides reliable results across all samples and populations aged 6-14.

Impact of state and trait anxiety severity on retention and phase advancement in an outpatient buprenorphine treatment program.

BACKGROUND AND OBJECTIVES: Comorbid anxiety is common among buprenorphine patients and may lead to poorer outcomes. This study aimed to examine the prevalence and impact of anxiety severity, measured by the State-Trait Anxiety Inventory (STAI) form Y-1 & Y2 scale, on treatment outcomes (retention and phase advancement) among outpatient buprenorphine-treated patients. METHODS: A retrospective chart review of 94 patients admitted to an outpatient buprenorphine treatment program was conducted. Patients were dichotomized into high and low severity groups based upon an STAI State Anxiety (S-Anxiety) and STAI Trait Anxiety (T-Anxiety) score ≥60 and <60, respectively. Associations of anxiety severity on successful phase advancement and retention during the first 90 days of treatment were assessed. RESULTS: Twenty-one of 94 (22%) participants reported high S-Anxiety and had a significantly greater likelihood of phase advancement (OR = 12.80, 95% CI = [1.19, 136.71]) than those with low S-Anxiety. No significant associations were found between either S-Anxiety or T-Anxiety and treatment retention. Current alcohol use and UDS negative test results for THC or amphetamines were each associated with phase advancement. THC negative UDS test results were associated with 90-day treatment retention. DISCUSSION AND CONCLUSIONS: Contrary to prior reports, buprenorphine patients with higher state anxiety severity demonstrated similar retention and more rapid phase advancement than those with lower state anxiety severity. SCIENTIFIC SIGNIFICANCE: To our knowledge, this is the first study to quantify current anxiety severity using the STAI scale and evaluate its impact on treatment outcomes among buprenorphine-treated patients.